Followers | 52 |
Posts | 10894 |
Boards Moderated | 11 |
Alias Born | 06/25/2009 |
Tuesday, March 21, 2023 9:16:07 PM
LEXI's board of directors has granted certain directors and officers of the Company options to purchase up to 4,000,000 common shares with a term of three years and an exercise price equal to $0.20 per share.
Early Warning Matters
Arena.
Arena acquired 30,000,000 common shares of LEXI and 37,166,666 share purchase warrants pursuant to the Transactions. After the Closing of the Transactions, Arena now beneficially owns or controls 30,064,500 common shares representing approximately 20.1% of LEXI's issued and outstanding common shares on a non-diluted basis and 37% on a partially diluted basis, assuming the exercise of all warrants held by Arena.
Prior to the Transactions, Arena beneficially owned or controlled 64,500 common shares of LEXI.
The common shares were acquired by Arena for investment purposes. Arena has a long-term view of the investment and may acquire additional securities of the Company including on the open market or through private acquisitions or sell securities of the Company including on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.
A copy of Arena's early warning report will appear on the Company's profile on SEDAR.
If THEIR IS ONE THING I AM SURE ABOUT IS I AM USUALLY WRONG
Recent LEXI News
- LEXI Upgraded to OTCQB Venture Market in the United States • Business Wire • 11/01/2023 12:01:00 PM
- LEXI Announces Appointment of Jason Nalewanyj as Chief Financial Officer and Highlights Significant Company Progress • Business Wire • 09/15/2023 02:17:00 PM
- LEXI Begins Next Phase of Lithium Exploration at Antofalla South Project • Business Wire • 08/01/2023 12:01:00 PM
- LEXI Begins Lithium Drilling in Antofalla North • Business Wire • 06/13/2023 11:40:00 AM
- LEXI Announces Details of Antofalla North Project Drilling Plan • Business Wire • 05/10/2023 12:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM